摘要
目的:对比分析盐酸表柔比星联合环磷酰胺序贯多西他赛(EC→T)与盐酸表柔比星、环磷酰胺联合多西他赛(TEC)两种新辅助化疗方案治疗乳腺癌的疗效及不良反应。方法:回顾性分析2013—2016年本院收治的Ⅱ~Ⅲ期乳腺癌新辅助化疗患者52例的临床资料,分别于术前接受3~4个周期的EC→T方案(n=22)或TEC方案(n=30)的新辅助化疗。结果:EC→T方案的CR为0例,PR为16例,有效率为72.73%;TEC方案的CR为2例,PR为24例,有效率为86.67%,两组有效率比较差异无统计学意义(P>0.05)。EC→T组骨髓抑制及脱发程度均轻于TEC组(P<0.05)。结论:EC→T与TEC两种新辅助化疗方案近期疗效相似,但后者不良反应重于前者。EC→T方案在新辅助化疗中有一定的应用前景。
Objective:To compare the curative effect and adverse reactions between EC-T and TEC regimens as neoadjuvant chemotherapy for breast cancer patients.Methods:A retrospectively analysis was made in the clinical data of 52 patients with stage H-IH breast cancer treated in our hospital from 2013 to 2016.Patients received preoperative neoadjuvant chemotherapy with EC->T(n=22)orT E C(n=30)regimen for 31 periods.Results:In EC->T group,no case reached CR,16 cases reached PR,and the effective rate was 76.73%;in TEC group,2 cases reached CR,24 cases reached PR,and the effective rate was 86.67%;there was no significant difference in the effective rate between the two groups(P>0.05).The degrees of marrow depression and hair loss were significantly mild in EC-T group compared with those in TEC group(P<0.05).Conclusion:The short-term efficacy of the two regimens as neoadjuvant chemotherapy is similar for patients with stage II-IH breast cancer.However,the adverse effect of TEC regimen is severer than that of EC->T regimen.EC->T regimen has more application prospect for the neoadjuvant chemotherapy in breast cancer patients.
作者
李佳珍
权毅
LI Jiazhen;QUAN Yi
出处
《现代临床医学》
2018年第2期123-124,127,共3页
Journal of Modern Clinical Medicine
关键词
乳腺癌
新辅助化疗
疗效
不良反应
breast cancer
neoadjuvant chemotherapy
curative effect
adverse effect
